Dr. Cloven is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
500 south henderson
Fort Worth, TX 76104Phone+1 817-413-1500- Is this information wrong?
Summary
Education & Training
- University of California (Irvine)Fellowship, Gynecologic Oncology, 1997 - 2001
- University of California (Irvine)Residency, Obstetrics and Gynecology, 1993 - 1997
- Baylor College of MedicineClass of 1993
- University of TexasBA, Biology, 1985 - 1989
Certifications & Licensure
- TX State Medical License 1994 - 2024
- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Awards, Honors, & Recognition
- Outstanding Preceptor UNT Health Science Center, PA studies, 2011-2017
- Top Doctors Fort Worth Texas Magazine, 2011-2017
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
- Join now to see all
Clinical Trials
- Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin Start of enrollment: 2006 Apr 01
- Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Start of enrollment: 2009 Apr 01
- Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Start of enrollment: 2009 Mar 23
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3...Domenica Lorusso, Yang Xiang, Kosei Hasegawa, Giovanni Scambia, Manuel Leiva, Pier Ramos-Elias, Alejandro Acevedo, Vladyslav Sukhin, Noelle Cloven, Andrea J Pereira de...> ;Lancet. 2024 Apr 6
- Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/EN...Pothuri, B., Han, S., Chase, D., Heitz, F., Burger, R., Gaba, L., Van Le, L., Guerra, E., Bender, D., Korach, J., Cloven, N., Churruca, C., Follana, P., DiSilvestro, P...> ;Gynecologic Oncology. 2024 Feb 6
- 1 citationsNiraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study (MOONSTONE/GOG-3032).Leslie M Randall, David M O'Malley, Bradley J Monk, Robert L Coleman, Stephanie Gaillard, Sarah Adams, Linda R Duska, Heather Dalton, Robert W Holloway, Marilyn Huang,...> ;Gynecologic Oncology. 2023 Nov 1
- Join now to see all
Journal Articles
- Velaparib with First-Line Chemotherapy and as Maintenance therapy in ovarian cancercoleman, NEJM, 9/28/2019
- We need a new paradigm in gynecologic cancer care: SGO proposes solutions for delivery, quality and reimbursement policiesRonald D. Alvarez ; Heidi J. Gray ; Patrick F. Timmins ; Randall K. Gibb ; Mitchell Edelson ; Jeffrey M. Fowler ; Laura J. Havrilesky ; Dayna L. McCauley ; John D. Nas..., Gyncol Oncol, 1/1/2013
- In Vitro Chemoresistance and Biomarker Profiles are Unique for Histologic Subtypes of Epithelial Ovarian CancerGillette Cloven, N, Kyshtoobayeva A, Burger RA, Yu IN, Fruehaf JP., Gynecologic-Oncology, 1/1/2004
- Join now to see all
Abstracts/Posters
- Ovarian Cancer in the Elderly: Trends in Survival over 30 years.Tierney B, Crotzer D, Morris P, Cloven N., 41 st Annual Meeting of the Society of Gynecologic Oncologists, San Francisco CA, 1/13/2010
- Outcomes of intermediate risk endometrial cancer without whole pelvis radiation therapy.Tierney BJ, Larsen G, Simons M, Crotzer D, Cloven NG, Morris PC, Western Association of Gynecologic Oncologists, Sonoma CA, 1/11/2008
- Does thorough surgical staging eliminate the need for radiation therapy in high intermediate risk endometrial cancer?Tierney BJ, Larsen G, Simons M, Crotzer D, Morris PC, Cloven NG, 39 th Annual Meeting of the Society of Gynecologic Oncologists, Tampa FL, 1/1/2008
- Join now to see all
Lectures
- Personalized Medicine: The Future is hereJoan Katz Breast Center, Fort Worth, Tx - 9/25/2016
- Robotic Surgery in GynecologyForth Worth, TX - 1/6/2011
- Benign and Malignant Vulvar DiseasesMethodist Estabrook Cancer Center - 1/19/2008
- Join now to see all
Authored Content
- myths about gynecologic cancerSeptember 2019
Press Mentions
- Gynecologic Cancer Awareness Month Draws Attention to Disparities in Endometrial CancerSeptember 22nd, 2022
- 3 Questions to Ask Your Oncologist About Clinical TrialsAugust 31st, 2021
- Obesity-Related Cancer Deaths Are on the RiseJune 17th, 2019
- Join now to see all
Research History
- Network PIPhase II study of Niraparib ( PARP) for recurrent ovarian cancer2014 - Present
- Asssociate Chair of Gynecologic Cancer Committee2011 - Present
Professional Memberships
- Member
- Society of Gynecologic OncologistMember
- Fort Worth Surgical SocietyMember
Hospital Affiliations
- Baylor Scott & White All Saints Medical Center - Fort WorthFort Worth, Texas
- Texas Health Harris Methodist Hospital Fort WorthFort Worth, Texas
External Links
- sgohttp://sgo.org
- texas oncologyhttp://texasoncology.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: